ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics for personalised medicine, provides an update on recent activity and progress:
The Company confirms that VAL201, its leading anti-cancer therapeutic, continues to progress through its clinical development on all fronts. This is a "First-in-(Hu)Man"study involving cancer patients, as opposed to healthy volunteers, and is a phase 1 trial.
It should be noted that activity on VAL201, that includes the required scientific, ethical, technical and legal work, with all supporting evidential material and documentation needed to finalise the reporting of the study (of which the trial forms part), is proceeding according to plan. Currently, all tasks that can or could impact the critical path of the VAL201 development programme are understood and controlled and none is giving undue concern that the outcome or the timing of the study will be adversely affected.
As previously reported on 13 June 2013, ValiRx anticipates that results of the phase 1 trial will be available before the end of 2013.
VAL101, the lead candidate deriving from the GeneICE platform, is progressing to the final preclinical "proof of concept" stage with pharmacokinetics (PK) and pharmacodynamics (PD) and preliminary toxicology studies underway. The work is being undertaken at the University of Heidelberg, Germany, which is the centre at which the lead investigator is now based following a move from Imperial College in London in the spring of this year.
The Eurostars grant that was previously awarded to a consortium led by ValiRx has now been successfully completed and this completion has been accepted by both the Technology Strategy Board (TSB) and the Eurostars Team. Furthermore, the Company has received notification from the TSB and Eurostars Team that it is eligible for a new grant which includes work on VAL101 and Biomarkers.
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
ValiFinn is the biomarkers and diagnostic development division
ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.
This information is provided by RNS
The company news service from the London Stock Exchange
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.